palazestrant (OP-1250) / Olema Pharma 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
palazestrant (OP-1250) / Olema Pharma
OPERA-01, NCT06016738: OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

Recruiting
3
510
Europe, Canada, US, RoW
Palazestrant, OP-1250, Fulvestrant, Anastrozole, Letrozole, Exemestane
Olema Pharmaceuticals, Inc.
Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, HER2 Negative Breast Carcinoma
06/26
09/27
OP-1250-001, NCT04505826: A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer

Active, not recruiting
2
153
US, RoW
OP-1250
Olema Pharmaceuticals, Inc.
Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer
06/24
07/24
ACTRN12621001419853p: A Study of OP-1250 in Combination with the CDK4/6 Inhibitor Palbociclib in Adult Subjects with Advanced or Metastatic hormone receptor-positive (HR-positive), human epidermal growth factor receptor 2-negative (HER2-negative) Breast Cancer

Not yet recruiting
1
30
 
Olema Pharmaceuticals, Inc., Olema Pharmaceuticals, Inc.
Breast Cancer
 
 
ACTRN12621001419853: A Study of OP-1250 in Combination with the CDK4/6 Inhibitor Palbociclib in Adult Subjects with Advanced or Metastatic hormone receptor-positive (HR-positive), human epidermal growth factor receptor 2-negative (HER2-negative) Breast Cancer

Recruiting
1
30
 
Olema Pharmaceuticals, Inc., Olema Pharmaceuticals, Inc.
Breast Cancer
 
 
OP-1250-002, NCT05266105: A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients

Active, not recruiting
1
60
RoW
Palazestrant, OP-1250, Palbociclib, Ibrance®️
Olema Pharmaceuticals, Inc., Pfizer
Breast Cancer
01/25
07/25
NCT05508906: Phase 1b Combo w/ Ribociclib and Alpelisib

Recruiting
1
90
US, RoW
OP-1250, Ribociclib, KISQALI, Alpelisib, PIQRAY
Olema Pharmaceuticals, Inc., Novartis
Metastatic Breast Cancer, Advanced Breast Cancer, HR-positive Breast Cancer, HER2-negative Breast Cancer
08/24
08/24

Download Options